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ORIGINAL ARTICLE
Sensitivity to Change and Minimal Important
Differences of the LupusQoL in Patients With
Systemic Lupus Erythematosus
KATHLEEN McELHONE,1 JANICE ABBOTT,2 CHRIS SUTTON,2 MONTANA MULLEN,2
PETER LANYON,3 ANISUR RAHMAN,4 CHEE-SENG YEE,5 MOHAMMED AKIL,6 IAN N. BRUCE,7
YASMEEN AHMAD,8 CAROLINE GORDON,9 AND LEE-SUAN TEH1
Objective. As a health-related quality of life (HRQOL) measure, the LupusQoL is a reliable and valid measure for
adults with systemic lupus erythematosus (SLE). This study evaluates the responsiveness and minimal important dif-
ferences (MIDs) for the 8 LupusQoL domains.
Methods. Patients experiencing a flare were recruited from 9 UK centers. At each of the 10 monthly visits, HRQOL
(LupusQoL, Short Form 36 health survey [SF-36]), global rating of change (GRC), and disease activity using the British Isles
Lupus Assessment Group 2004 index were assessed. The responsiveness of the LupusQoL and the SF-36 was evaluated pri-
marily when patients reported an improvement or deterioration on the GRC scale and additionally with changes in physician-
reported disease activity. MIDswere estimated asmean changes whenminimal changewas reported on the GRC scale.
Results. A total of 101 patients were recruited. For all LupusQoL domains, mean HRQOL worsened when patients
reported deterioration and improved when patients reported an improvement in GRC; SF-36 domains showed compa-
rable responsiveness. Improvement in some domains of the LupusQoL/SF-36 was observed with a decrease in disease
activity, but when disease activity worsened, there was no significant change. LupusQoL MID estimates for deteriora-
tion ranged from 22.4 to 28.7, and for improvement from 3.5 to 7.3; for the SF-36, the same MID estimates were 22.0
to 211.1 and 2.8 to 10.9, respectively.
Conclusion. All LupusQoL domains are sensitive to change with patient-reported deterioration or improvement in
health status. For disease activity, some LupusQoL domains showed responsiveness when there was improvement but
none for deterioration. LupusQoL items were derived from SLE patients and provide the advantage of disease-specific
domains, important to the patients, not captured by the SF-36.
INTRODUCTION
The survival of patients with systemic lupus erythemato-
sus (SLE) has improved in the last 50 years from less than
50% at 5 years in 1955 to 85% at 10 years and recently, 75%
at 20 years (1). The Outcome Measures in Rheumatology
Clinical Trials group and the US Food and Drug
Administration (FDA) have recommended that for clinical
trials and observational studies, health-related quality of
life (HRQOL) should be assessed using both generic and
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disease-specific measures, allowing comparison with
healthy samples, estimates of health utilities, and disease-
specific information known to be important to patients
(2,3). HRQOL instruments provide a standardized, valid,
and reliable way of gaining the patient’s perspective as to
how they are affected by SLE and the benefits and limita-
tions of interventions. HRQOL in SLE is poorly correlated
with the clinicians’ assessment of disease activity and
damage (4,5), as some symptoms are only known to the
patient (e.g., fatigue, nausea). Therefore, HRQOL measure-
ment can provide added value because it can supply infor-
mation not captured by other outcome measures. HRQOL
may be informative not only as an efficacy measure, but it
also potentially reflects safety issues, and for these reasons
HRQOL is becoming important in labeling claims (6,7).
The LupusQoL is a valid, reliable, patient-derived,
disease-specific HRQOL measure for adults with SLE (8)
that contains items/domains more relevant to patients
with SLE than generic measures (9). As with many
HRQOL measures, the interpretation of the data may be
problematic and should not be based solely on P values,
especially if HRQOL is a secondary outcome when a trial
tends not to be powered for HRQOL. To aid the interpreta-
tion of the LupusQoL, evaluation is required to assess its
sensitivity to change (the ability to detect an improvement
or deterioration when patients deem themselves to have
improved or deteriorated) (10) as advocated by the regula-
tory bodies (2), and to estimate the minimal important dif-
ference (MID), the smallest difference that patients
perceive as beneficial or harmful (11).
This study aimed to evaluate these parameters, using
both anchor-based and distribution-based methods, for
each domain of the LupusQoL and the Short Form 36
health survey (SF-36). Specifically, the study looked at the
ability of the scales to detect an improvement in HRQOL
following treatment of a severe or moderate flare, to detect
deterioration in HRQOL (e.g., when patients fail to have
their disease controlled by their initial treatment plan),
and to estimate the MIDs. The responsiveness of the
LupusQoL and the SF-36 was evaluated primarily when
patients reported an improvement or deterioration on the
global rating of change (GRC) scale (12) and, second, with
changes in physician-reported disease activity.
PATIENTS AND METHODS
Study design. This was a prospective, longitudinal,
observational study. The study was granted multicenter
Research Ethics Committee approval (MREC 02/05/035)
and was carried out in compliance with the Helsinki
Declaration at the following rheumatology units: Bangor,
Birmingham (2 centers), Blackburn, University College
London, Nottingham, Manchester, Doncaster, and Sheffield.
All patients gave written informed consent.
Patient inclusion and exclusion. Patients were recruited
over an 18-month period and were followed at 4-week (6 2
weeks) intervals for 9 months. The inclusion criteria were
fulfillment of $4 American College of Rheumatology (ACR)
criteria for SLE (13,14), ages$16 years, literate ability in the
English language, willingness to give written informed con-
sent, and a flare of SLE requiring specific treatment. A flare
was defined as a significant increase in disease activity,
resulting in a British Isles Lupus Assessment Group 2004
(BILAG-2004) index A or B score, based on criteria that are
new or worse (15–17). To be included in this study, patients
had to require an increase in therapy defined as $1 of the
following: an increase of oral prednisolone to $20 mg/day,
introduction of methotrexate, parenteral methylpredniso-
lone, and/or other immunosuppressive therapy (e.g., cyclo-
phosphamide, rituximab). The exclusion criteria were ages
,16 years, inability to read English, inability to give valid
consent, and pregnancy.
Assessment measures. Demographic and clinical
details were recorded at baseline by the clinician (date of
birth, sex, date of diagnosis, fulfilment of ACR criteria for
SLE, ethnic group [18], marital status, and current ther-
apy). The Systemic Lupus International Collaborating
Clinics/ACR Damage Index (SDI) (19) was reported twice,
at baseline and at the end of the study. The BILAG-2004
disease activity index was assessed at each visit.
Significance & Innovations
 The LupusQoL, a patient-derived disease-specific
health-related quality of life (HRQOL) measure
for adults is sensitive to change in health status
and can be recommended for use in clinical trials.
 The LupusQoL domain minimal important dif-
ferences for deterioration range from 22.4 to
28.7 and for improvement from 3.5 to 7.3.
 LupusQoL items were derived from systemic lupus
erythematosus patients and provide the advantage
of disease-specific domains, important to them, not
captured by the Short Form 36 health survey.
 These results will allow appropriate power
calculations and interpretation of HRQOL
measurements in clinical trials and longitudinal
observational studies.
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The original English version of the LupusQoL (4-week
recall period) (8) was completed by the participant at each
time point. It has 8 domains: physical health, pain, plan-
ning, body image, burden to others, intimate relationships,
emotional health, and fatigue. This instrument has good
internal reliability (Cronbach’s a50.88–0.96), test–retest
reliability (intraclass correlation coefficient [ICC] 0.72–0.93),
and concurrent validity with comparable domains of the
SF-36 (ICC 0.71–0.79). It has acceptable ceiling effects and
minimal floor effects. Scoring of each domain of the
LupusQoL is such that 05worst health and 1005best
health (8).
Patients completed the SF-36 (UK version 1) with a
4-week recall at each assessment (20). The SF-36 measures
8 dimensions of health: physical functioning, social func-
tioning, role limitations due to physical problems, role
limitations due to emotional problems, mental health,
energy/vitality, bodily pain, and general health percep-
tion. Domain scores can range from 0 to 100 (higher scores
indicate a better HRQOL).
To estimate patient-reported change, each domain of
the LupusQoL and the SF-36 incorporated the GRC scale
(12). Patients were asked to rate change in each domain
over the past 4 weeks from 7 (a very great deal better) to
27 (a very great deal worse) with 0 indicating no change.
Scores of 21 to 1 were classified as no change, with 27 to
22 as deterioration and 2 to 7 as improvement. Within the
deterioration and improvement categories, scores of 2, 3,
22, and 23 were considered to represent minimal, but
nevertheless, important changes.
At baseline and each review visit, the clinician assessed
the SLE disease activity using the BILAG-2004 index (15).
The BILAG-2004 category scores A to E are based on
intention to treat, where A5 severe disease activity,
B5moderate disease activity, C5mild, stable disease,
D5 inactive disease but previously affected system, and
E5 a system that has never been involved. Changes in
overall disease activity between consecutive time points,
as measured by the BILAG-2004 index, were defined as
follows: 1) deterioration, with any system changing to A
from B/C/D or to B from C/D (21); 2) improvement, with
all systems changing from A to B/C/D and B scores chang-
ing to C/D (22), with no deterioration in any system (one
persistent B score was allowed if there was improvement
from A or B in at least 1 other system); 3) persistent inac-
tive disease, with all systems scored as C/D/E at both time
points; and 4) persistent active disease, with A or B sys-
tem scores remaining unchanged but without overall
improvement or deterioration. When changes of activity of
a single BILAG system were analyzed, the above defini-
tions applied, but only for that system, and no persistent
B score was allowable for improvement.
Statistical methods. The sample size calculation was
based on summary statistics from previous work during
the LupusQoL development and based on the changes of
the physical health domain. A sample size of 52 would
have 80% power to detect a difference in means of 4,
assuming an SD of 10, using a paired t-test with a 5% sig-
nificance level. The intention was to recruit 104 patients,
to allow for patients who did not report changes in
HRQOL, expected smaller effect size for the other
domains, missing data, and dropouts. All analyses were
performed using Stata Release software, version 13 (23).
Determination of sensitivity to change (res-
ponsiveness). The primary method for assessing respon-
siveness was based on patient-reported GRC scores.
Responsiveness was also examined using physician-
reported disease activity change scores. Based on GRC or
disease activity change scores, each domain of both
HRQOL measures was evaluated to determine its ability to
detect an improvement in HRQOL following treatment of
a flare and to detect deterioration in HRQOL (e.g., when
treatment has undesirable and troublesome side effects or
the patients fail to have their disease controlled by their
initial treatment plan). Responsiveness was estimated as the
mean change in HRQOL domain score across participant-
reported improvements or improvement of disease activity,
and across participant-reported deteriorations or deteriora-
tion of disease activity, between consecutive assessments.
We calculated 95% confidence intervals (95% CIs) using
robust methods for estimating the standard error in Stata,
based on the approach proposed by Huber (24).
Additionally, standardized response means (SRMs), the
ratio of the mean change of the domain score between con-
secutive observations and the corresponding estimated SD
of the change score, were reported based on GRC scores.
Effect sizes, for which the mean change of each domain
score was standardized using the estimated SD of the
baseline score, were also reported based on GRC scores.
Both are standardized measures of responsiveness, with
the SRM having the advantage that it is less affected by
the heterogeneity of the sample by using a more appropri-
ate SD, namely that of the change score. SRMs or effect
sizes of 0.2, 0.5, and 0.8 are deemed to demonstrate small,
moderate, or large responsiveness, respectively (25).
Figure 1. Flow diagram of patient progress through study
procedures.
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We also explored changes in relevant domains of the
LupusQoL and SF-36 to changes of key systems in the
BILAG-2004 index. The musculoskeletal and mucocutane-
ous systems are the most commonly affected systems in
SLE patients, and therefore we explored the relationships
between musculoskeletal system changes and the changes
in physical health and pain domains of the LupusQoL and
the changes in physical functioning and bodily pain
domains of the SF-36. We also explored the mucocutane-
ous system changes and the changes in the body image
domain of the LupusQoL.
Estimation of MIDs. Methods for estimating the MID
are either anchor-based (sometimes referred to as mini-
mum clinically important difference) or distribution-
based. We use the term MID as this is the more dominant
term in the current literature (26) for both approaches, as
ultimately they seek to establish the same property. We
will illustrate the difference in the methodology by using
MID(a) for the anchor-based approach or MID(d) for the
distribution-based approach. No single approach is per-
fect, and multiple strategies are likely to enhance the
interpretability of changes in HRQOL scales (11,27). An
anchor-based method was used as the primary approach
(as preferred by the FDA) (2), based on the average change
in LupusQoL or SF-36 scores for the subset of patients
who were considered to have a small but discernible cha-
nge in that particular HRQOL domain. These analyses
were complemented by distribution-based approaches
based around the common standards of 1 SEM, using data
from McElhone et al (8) and 0.5 SD, which corresponds to
a medium effect (28,29).
RESULTS
Patient recruitment and followup. During the 18-
month recruitment period, a total of 115 patients from 9
centers were deemed eligible for the study and
approached. Four patients declined to participate and 111
patients were recruited. Of these, 101 patients completed
the study and are reported here (Figure 1).
Patient demographics, disease activity, and
damage. The baseline demographic and clinical charac-
teristics and HRQOL of the patients are provided in
Tables 1 and 2. There were 42 A flares in 41 patients (one
patient had A flares in both musculoskeletal and mucocu-
taneous systems) and 130 B flares, with some patients hav-
ing both A and B flares. The frequency of flares in the
different BILAG-2004 systems is shown in Supplementary
Table 1 (available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.22850/abstract). Only 28% of the patients scored $1
for damage on the SDI (Table 2).
Table 1. Patient baseline demographic and clinical
characteristics*
Female 95 (94)
Age, mean6SD years 40.9612.8
Disease duration, mean6SD years 9.368.1
Ethnic distribution (n599)
White (British, Irish) 62 (63)
Black (Caribbean, African) 12 (12)
Asian (Indian, Pakistani, Bangladeshi) 14 (14)
Chinese 1 (1)
Other Asian 3 (3)
Mixed 7 (7)
Clinical characteristics (ACR criteria)
Malar rash 43 (43)
Photosensitivity rash 47 (47)
Discoid rash 12 (12)
Mouth ulcers 47 (47)
Arthritis 92 (91)
Serositis 45 (45)
Renal disease 21 (21)
Central nervous system disease 8 (8)
Hematologic disease 73 (72)
Positive antinuclear antibodies 96 (95)
Positive dsDNA, Sm, or APA antibodies 80 (79)
Marital status (n5 94)
Married 53 (56)
Single 36 (38)
Divorced 5 (5)
* Values are the number (%) unless stated otherwise. ACR5
American College of Rheumatology; dsDNA5double-stranded DNA.
Table 2. Patient baseline disease activity, damage, and
health-related quality of life*
BILAG-2004 index 16.46 8.1
SLICC/ACR DI (n5 98) 0.566 1.18
SLICC/ACR DI, no. (%)
Score of 0 71 (72)
Score of 1 14 (14)
Score of 2 6 (6)
Score of $3 7 (7)
LupusQoL domain scores
Physical health 42.66 26.6
Pain 40.96 28.0
Planning 46.46 32.2
Intimate relationships 37.86 33.5
Burden to others 33.36 28.2
Emotional health 51.46 25.8
Body image 45.56 29.1
Fatigue 34.16 26.0
SF-36 domain scores
Physical functioning 38.16 26.9
Bodily pain 31.86 23.1
Social functioning 42.36 29.7
General health perceptions 25.06 18.6
Role emotional 28.76 39.4
Mental health 51.06 21.5
Role physical 12.16 27.5
Vitality 21.96 20.0
* Values are mean6SD unless indicated otherwise. BILAG-20045
British Isles Lupus Assessment Group 2004; SLICC5 Systemic
Lupus International Collaborating Clinics; ACR5 American College
of Rheumatology; DI5damage index; SF-365 Short Form 36 health
survey.
1508 McElhone et al
HRQOL: LupusQoL and SF-36 at baseline
(flare). HRQOL was severely impaired at baseline, with
mean LupusQoL scores ranging from 33.3 (burden to
others) to 51.4 (emotional health), while mean SF-36
domain scores ranged from 12.1 (role physical) to 51.0
(mental health) (Table 2). Scores for comparable LupusQoL/
SF-36 domains were highly correlated (pain/bodily pain
r5 0.76; physical health/physical function r5 0.82; emo-
tional health/mental health r5 0.74; fatigue/vitality
r5 0.66), although observed mean scores were consistently
higher for LupusQoL than for SF-36 domains (Table 2).
Sensitivity to change (responsiveness). There were 911
(90.2%) completed HRQOL questionnaires across the 10
time points. The amount of complete change score data,
however, varied across HRQOL domains and time points.
For the LupusQoL, 6 of the 8 domains had .83% of
change score data available, ranging from 776 (85.4%) for
physical health to 757 (83.3%) for fatigue, with the other
domains having lower percentages of change score data
available (body image 616 [67.8%] and intimate relation-
ships 541 [59.5%]). For the SF-36 the amount of change
score data available ranged from 773 (85.0%) for general
health to 761 (83.7%) for role physical.
All domains of the LupusQoL worsened significantly
when patients reported a deterioration of their health sta-
tus, and all domains improved significantly when patients
reported an improvement in their health status (Tables 3
and 4). There was little change in the mean LupusQoL
scores when patients reported no change in their health
status (1, 0, and 21 on the GRC score). Mean change
scores ranged from 0.6 (95% CI 20.4, 1.6) in the physical
health domain to 2.5 (95% CI 1.2, 3.8) in the burden to
others domain. For deterioration, the mean LupusQoL
change scores ranged from 22.5 (95% CI 24.2, 20.8) for
the body image domain to 27.7 (95% CI 214.7, 20.6) for
the intimate relationships domain. For improvement, the
mean LupusQoL change scores ranged from 5.6 (95% CI
4.2, 7.1) in the physical health domain to 10.4 (95% CI
7.7, 13.1) in the burden to others domain. The results for
the SF-36 were similar.
When the overall disease activity lessened, 6 domains
of the LupusQoL (physical health, pain, planning, emo-
tional health, body image, and fatigue) and 7 of the SF-36
domains (physical functioning, bodily pain, mental
health, social functioning, role emotional, role physical,
and vitality) showed an improvement. For the remaining
LupusQoL and SF-36 domains, changes were small and
nonsignificant. When overall disease activity increased,
Table 3. Change in score of LupusQoL and SF-36 in comparable domains by global rating of
change category*
Deterioration (27 to 22) Stable (21 to 1) Improvement (2 to 7)
LupusQoL
Pain 26.5 (28.9, 24.1) [72, 195] 1.5 (0.2, 2.7) [89, 307] 9.3 (7.1, 11.5) [80, 258]
Physical health 23.7 (25.2, 22.1) [72, 188] 0.6 (20.4, 1.6) [90, 298] 5.6 (4.2, 7.1) [83, 282]
Emotional health 24.4 (26.0, 22.7) [78, 213] 1.2 (0.1, 2.3) [92, 304] 6.2 (4.7, 7.8) [74, 243]
Fatigue 24.6 (26.5, 22.8) [81, 256] 2.1 (0.6, 3.6) [88, 296] 8.9 (6.8, 11.0) [62, 203]
SF-36
Bodily pain 27.0 (29.3, 24.7) [86, 254] 2.8 (1.1, 4.5) [80, 263] 13.0 (10.6, 15.4) [74, 231]
Physical functioning 23.0 (24.3, 21.6) [75, 209] 1.2 (0.3, 2.2) [89, 293] 5.6 (3.9, 7.3) [77, 249]
Mental health 25.5 (27.5, 23.6) [80, 234] 20.1 (21.6, 1.4) [84, 283] 7.6 (5.9, 9.4) [72, 238]
Vitality 24.6 (26.3, 22.8) [85, 286] 0.9 (20.8, 2.6) [86, 283] 11.2 (8.4, 14.0) [62, 188]
* Values are mean (95% confidence interval) [number of contributing participants, number of valid change observations].
Totals5 [101, 776]. SF-365Short Form 36 health survey.
Table 4. Change in score of LupusQoL and SF-36 in noncomparable domains by global rating of
change category*
Deterioration (27 to 22) Stable (21 to 1) Improvement (2 to 7)
LupusQoL
Body image 22.5 (24.2, 20.8) [67, 197] 1.4 (0.3, 2.5) [79, 296] 6.4 (3.6, 9.2) [47, 122]
Planning 24.6 (27.0, 22.2) [64, 164] 1.2 (0.0, 2.4) [93, 391] 6.3 (3.9, 8.8) [65, 206]
Intimate relationships 27.7 (214.7, 20.6) [42, 75] 0.9 (21.0, 2.8) [74, 338] 8.3 (4.3, 12.4) [45, 120]
Burden to others 24.6 (26.9, 22.3) [70, 195] 2.5 (1.2, 3.8) [94, 397] 10.4 (7.7, 13.1) [57, 167]
SF-36
General health 22.0 (23.2, 20.8) [84, 240] 0.3 (20.6, 1.2) [87, 265] 3.4 (2.2, 4.6) [79, 259]
Role emotional 210.1 (215.9, 24.3) [69, 182] 2.6 (20.3, 5.4) [89, 363] 11.3 (6.6, 15.9) [67, 204]
Role physical 29.9 (215.3, 24.5) [71, 185] 1.4 (21.3, 4.0) [90, 339] 14.7 (9.9, 19.5) [72, 223]
Social functioning 27.0 (210.8, 23.1) [69, 178] 1.6 (0.1, 3.2) [92, 390] 10.1 (7.0, 13.2) [66, 190]
* Values are mean (95% confidence interval) [number of contributing participants, number of valid change observations].
Totals5 [101, 776]. SF-365Short Form 36 health survey.
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there was no significant decrease in any of the scores of
the LupusQoL or SF-36 domains (see Supplementary
Tables 2 and 3, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.22850/abstract). An improvement in the disease activity
of the musculoskeletal system was associated with signifi-
cant improvements in both the LupusQoL and SF-36
physical function and pain domains. When the disease
activity worsened, only a significant deterioration of the
LupusQoL pain domain was observed, although numbers
of patients were low. When disease activity altered on
the mucocutaneous system, no significant change was
observed in the LupusQoL body image domain (see
Supplementary Table 4, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/
10.1002/acr.22850/abstract).
For deterioration in GRC, LupusQoL domain SRMs
ranged from 20.16 (body image) to 20.35 (pain), and
those for SF-36 ranged from 20.22 (general health) to
20.38 (bodily pain). For comparable domains, LupusQoL
SRMs were similar in size to SF-36 SRMs (see
Supplementary Table 5, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/
10.1002/acr.22850/abstract). For improvement, LupusQoL
domain SRMs ranged from 0.36 (planning and intimate
relationships) to 0.55 (burden to others), and those for SF-
36 ranged from 0.25 (role emotional) to 0.61 (bodily pain).
For comparable domains, LupusQoL and SF-36 SRMs
were similar in size. For effect sizes, patterns of sensitivity
to change measures were similar (see Supplementary
Table 6, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.
22850/abstract).
MID results. Using the anchor-based approach, the
MID(a)s for improvement and for deterioration for each of
the LupusQoL and SF-36 domains are given in Table 5.
For deterioration, the mean MID(a) for the LupusQoL
ranged from 22.4 (95% CI 24.8, 0.1) for body image to
28.7 (95% CI218.9, 1.6) for intimate relationships, and for
improvement from 3.5 (95% CI 0.5, 6.5) for body image to
7.3 (95% CI 4.0, 10.6) for burden to others. For the SF-36,
for deterioration, the mean MID(a) ranged from 22.0 (95%
CI 23.4, 20.5) for general health to 211.1 (95% CI 217.8,
24.5) for role physical, and for improvement, the mean
MID(a) ranged from 2.8 (95% CI 1.2, 4.5) for general health
to 10.9 (95% CI 8.0, 13.8) for bodily pain and 10.9 (95% CI
7.5, 14.3) for vitality. For comparable domains, for both
deterioration and improvement, mean MID(a)s for
LupusQoL tended to be smaller in size than mean SF-36
MID(a)s (Table 5).
Compared to anchor-based approaches, using distribution-
based approaches based on 0.5 SD, LupusQoL domain
MID(d)s were larger still, but more consistent between
domains, ranging from 12.9 (emotional health) to 16.7 (inti-
mate relationships). For SF-36 domains, MID(d)s based on
0.5 SD were also larger, albeit relatively less so, ranging from
9.3 (general health perceptions) to 19.7 (role emotional).
Estimates of MID(d) using 1 SEM were larger than anchor-
based estimates, ranging from 6.6 for emotional health to
13.2 for burden to others (see Supplementary Table 7, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22850/abstract).
DISCUSSION
Knowing whether, or to what extent, a patient has
improved or deteriorated following a course of treatment is
fundamental to clinical practice. This work has demon-
strated that all 8 of the LupusQoL domains are sensitive to
change and able to identify patient-reported improvements
Table 5. Minimal important change estimates for LupusQoL and SF-36 in comparable and
noncomparable domains via anchor-based global rating of change category*
Deterioration (23 or 22) Improvement (2 or 3)
Comparable domains
LupusQoL pain 24.7 (27.6, 21.7) 6.8 (4.4, 9.1)
SF-36 bodily pain 26.7 (29.4, 24.0) 10.9 (8.0, 13.8)
LupusQoL physical health 23.4 (25.1, 21.8) 4.0 (2.2, 5.8)
SF-36 physical function 22.4 (24.3, 20.5) 3.8 (1.8, 5.8)
LupusQoL emotional health 23.7 (25.7, 21.7) 4.7 (2.6, 6.7)
SF-36 mental health 25.1 (27.1, 23.2) 7.5 (5.3, 9.8)
LupusQoL fatigue 23.2 (25.4, 21.0) 6.6 (4.0, 9.1)
SF-36 vitality 23.5 (25.5, 21.4) 10.9 (7.5, 14.3)
Noncomparable domains
LupusQoL body image 22.4 (24.8, 0.1) 3.5 (0.5, 6.5)
LupusQoL planning 24.0 (27.4, 20.6) 3.8 (0.9, 6.6)
LupusQoL intimate relationships 28.7 (218.9, 1.6) 7.1 (2.1, 12.2)
LupusQoL burden to others 25.0 (27.8, 22.1) 7.3 (4.0, 10.6)
SF-36 general health 22.0 (23.4, 20.5) 2.8 (1.2, 4.5)
SF-36 role emotional 210.4 (218.1, 22.7) 10.2 (2.4, 18.0)
SF-36 role physical 211.1 (217.8, 24.5) 10.8 (4.3, 17.4)
SF-36 social functioning 24.2 (28.8, 0.3) 9.6 (5.4, 13.8)
* Values are mean (95% confidence interval). SF-365Short Form 36 health survey.
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and deteriorations. With changes in physician-reported
disease activity, there were less consistent findings of
improvement in 6 of 8 LupusQoL domains when disease
activity lessened but little or no responsiveness with wors-
ening disease activity. There may be several reasons for this
difference: 1) physician-reported disease activity measures
a different concept from HRQOL, hence the FDA recom-
mendation that responsiveness should be measured against
the patient GRC, 2) patients may perceive improvement
more clearly than deterioration, particularly after having a
flare, 3) the number of patients in the deterioration sub-
groups, especially when single BILAG system changes
were examined, may be insufficient to detect significant
changes, and 4) the assessment over a month may be too
short a time period for change to occur in some domains of
the LupusQoL following a change in disease activity.
Different LupusQoL domains had different patient-
reported MID(a)s, which also differed for deterioration
and improvement. When looking for an improvement in
SLE, the MID ranges from 4 to 7 points, depending on the
domain. For the SF-36, the MIDs range from 3 to 11 points.
These results will allow appropriate power calculations
and interpretation of HRQOL measurements in clinical tri-
als and longitudinal observational studies. MIDs are not
without problems, in that different methodologies
(anchor-based or distribution-based) generated somewhat
different MIDs, and the MID reflects the difference that is
important at a group, but not the individual, level.
Regulatory bodies advocate the use of anchor-based
methods in the estimation of responsiveness as they use
patient ratings (2), even though the reliability of patients’
estimates of their previous health status has been
questioned (30,31).
This study recruited patients with moderate or severe
flares and is likely to be representative of patients recruited
into clinical trials. Notably, the original LupusQoL mean
scores derived from consecutive outpatients at UK centers
were strikingly higher (by approximately 20–25 points)
across all domains (8) than the baseline values for these
patients with moderate or severe flares. Such large differ-
ences suggest that a flare of SLE has a very significant
impact on all aspects of HRQOL and may also explain why
the LupusQoL is less responsive to deterioration of disease
activity, as patients already have poor health.
There have been 2 publications regarding the sensitivity
to change of the LupusQoL. Using the Canadian version of
the LupusQoL, Touma et al (32) concluded that its respon-
siveness was similar to that of the SF-36 following a 12-
month prospective cohort study of consecutive patients at
a single tertiary center. However, only changes in the dis-
ease activity measure, the Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2000) (33,34), were
used to estimate responsiveness, while in our study the
patient-reported GRC scale was used to estimate respon-
siveness as recommended by the regulatory bodies (2,3),
in addition to a disease activity measure (the BILAG-2004
index). Results of a multitertiary center cohort study, rec-
ruiting consecutive patients using the French version of
the LupusQoL, assessed patients at 3 and 6 months (35).
The anchors for improvement and deterioration included
a patient-reported 7-point Likert scale and visual analog
scale (100 mm). A Likert scale of 5 patient-reported symp-
toms extracted from the Systemic Lupus Assessment
Questionnaire (SLAQ) was also used (36,37). The French
language LupusQoL and the SF-36 showed comparable
responsiveness, and the MIDs were similar for both mea-
sures. Despite the different patient selection criteria (con-
secutive recruitment/SLE flare; single tertiary center/
multicenter study), length of followup period, different
methods (anchor-based, distribution-based), and scales to
evaluate sensitivity to change (GRC scale, SLAQ, SLEDAI-
2000), there is agreement that the LupusQoL demonstrates
sensitivity to change in SLE.
In this study that recruited patients with active lupus,
the LupusQoL and SF-36 appear to be more responsive to
improvement than deterioration; this result was also
noted in the French study (35). Researchers previously
reported that patients with other conditions detected
improvements following treatment more easily than dete-
rioration. Patients reported that they often did not realize
how much they had deteriorated until they started to
improve (38). This recognition is an encouraging finding,
especially when the LupusQoL is recommended for use in
clinical trials. When patients improve during and after an
intervention, the LupusQoL should be able to detect these
changes. In contrast, in a study of SLE patients that
employed the SF-36, deterioration of HRQOL was per-
ceived more readily than improvement (39). However,
that article described studies in a clinical trial setting,
using an immunologic anchor as a marker of
improvement.
In spite of a large data set and rigorous followup sched-
ule, our study had little missing change score data on
most domains (approximately 15%). The majority of
patients were white (62.6%), but other groups were repre-
sented, including 15.2% of South Asian origin. Although
monthly followups may not have allowed sufficient time
for an intervention to take effect and for some HRQOL
domains to change as different domains may change over
different periods of time, monthly reviews did ensure that
relapses and the effects of these on HRQOL were not
missed.
The assessment of lupus disease in clinical trials should
involve patient-reported outcomes, including a global
assessment and specific instruments that capture the
impact of the disease on the patient quality of life. The
LupusQoL has previously demonstrated good construct,
face, discriminative, and concurrent validity, and internal
and test–retest reliability, and has been mapped to the Short
Form in 6 dimensions (8,40,41). Linguistic validations have
enabled the instrument to be employed successfully in 51
countries using 77 different languages (42). This study dem-
onstrates the responsiveness of the instrument and further
construct validity as compared with the SF-36 and provides
the MIDs. The SF-36 and the LupusQoL are similar in terms
of responsiveness, but the items on the LupusQoL were
informed by patients with SLE, and therefore it has the
advantage of several SLE-specific domains that are impor-
tant to patients (planning, burden to others, intimate
relationships, and body image) (9) that are not captured by
the SF-36.
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